Literature DB >> 26857281

Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway.

Jun Li1, Zhangjun Song2, Yiyu Wang3, Yue Yin3, Ying Liu3, Rong Yuan3, Xing Nan3.   

Abstract

Sphingosine kinase 1 (SphK1) expression is elevated in various cancers and is associated with shorter survival times for patients. However, the molecular mechanism of SphK1 up-regulation in triple-negative breast cancer (TNBC) remains unclear. In this study, we assayed the expression level of SphK1 in TNBC tissues by qRT-PCR and immunohistochemistry. The level of S1P was quantified by ELISA in the serum of TNBC patients. Our results found that the levels of SphK1 and S1P were significantly increased in TNBC patients compared with normal control. Furthermore, knockdown of SphK1 with siRNA decreased TNBC cell proliferation and inhibited cell migration/invasion. These data suggest that SphK1 has an important role in TNBC and presents an attractive therapeutic target for the treatment for TNBC.

Entities:  

Keywords:  AKT; Chemotherapy; PI3K; Sphingosine kinase 1; Sphingosine-1-phosphate; Triple-negative breast cancer

Mesh：

Substances：

Year:  2016        PMID： 26857281     DOI： 10.1007/s13277-016-4954-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  20 in total

1.  Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens.

Authors:  Bernard Malavaud; Dimitri Pchejetski; Catherine Mazerolles; Geisilène Russano de Paiva; Cyril Calvet; Nicolas Doumerc; Stuart Pitson; Pascal Rischmann; Olivier Cuvillier
Journal:  Eur J Cancer       Date:  2010-10-20       Impact factor: 9.162

Review 2.  Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases.

Authors:  Nitai C Hait; Carole A Oskeritzian; Steven W Paugh; Sheldon Milstien; Sarah Spiegel
Journal:  Biochim Biophys Acta       Date:  2006-08-18

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs.

Authors:  Shuntaro Tsukamoto; Yuhui Huang; Motofumi Kumazoe; Connie Lesnick; Shuhei Yamada; Naoki Ueda; Takashi Suzuki; Shuya Yamashita; Yoon Hee Kim; Yoshinori Fujimura; Daisuke Miura; Neil E Kay; Tait D Shanafelt; Hirofumi Tachibana
Journal:  Mol Cancer Ther       Date:  2015-08-11       Impact factor: 6.261

5.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival.

Authors:  Laura G Fulford; Jorge S Reis-Filho; Ken Ryder; Chris Jones; Cheryl E Gillett; Andrew Hanby; Douglas Easton; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

Review 6.  Triple-negative breast cancer: new perspectives for targeted therapies.

Authors:  Federica Tomao; Anselmo Papa; Eleonora Zaccarelli; Luigi Rossi; Davide Caruso; Marina Minozzi; Patrizia Vici; Luigi Frati; Silverio Tomao
Journal:  Onco Targets Ther       Date:  2015-01-16       Impact factor: 4.147

7.  SPHK1 regulates proliferation and survival responses in triple-negative breast cancer.

Authors:  Arpita Datta; Ser Yue Loo; Baohua Huang; Lingkai Wong; Sheryl S L Tan; Tuan Zea Tan; Soo-Chin Lee; Jean Paul Thiery; Yaw Chyn Lim; Wei Peng Yong; Yulin Lam; Alan Prem Kumar; Celestial T Yap
Journal:  Oncotarget       Date:  2014-08-15

8.  Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer.

Authors:  Nidhi Bansal; Kevin Petrie; Rossitza Christova; Chi-Yeh Chung; Boris A Leibovitch; Louise Howell; Veronica Gil; Yordan Sbirkov; EunJee Lee; Joanna Wexler; Edgardo V Ariztia; Rajal Sharma; Jun Zhu; Emily Bernstein; Ming-Ming Zhou; Arthur Zelent; Eduardo Farias; Samuel Waxman
Journal:  Oncotarget       Date:  2015-10-27

9.  Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.

Authors:  Ming-Huang Chen; Chueh-Chuan Yen; Chi-Tung Cheng; Ren-Chin Wu; Shih-Chiang Huang; Chung-Shan Yu; Yi-Hsiu Chung; Chun-Yu Liu; Peter Mu-Hsin Chang; Yee Chao; Ming-Han Chen; Yu-Fen Chen; Kun-Chun Chiang; Ta-Sen Yeh; Tzu Chi Chen; Chi-Ying F Huang; Chun-Nan Yeh
Journal:  Oncotarget       Date:  2015-09-15

10.  ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer.

Authors:  Yan Liu; Michelle Baglia; Ying Zheng; William Blot; Ping-Ping Bao; Hui Cai; Sarah Nechuta; Wei Zheng; Qiuyin Cai; Xiao Ou Shu
Journal:  Oncotarget       Date:  2015-12-01
View more
  16 in total

1.  miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.

Authors:  Insaf Fkih M'hamed; Maud Privat; Mounir Trimeche; Frédérique Penault-Llorca; Yves-Jean Bignon; Abderraouf Kenani
Journal:  Pathol Oncol Res       Date:  2017-01-18       Impact factor: 3.201

2.  A novel sphingosine kinase 1 inhibitor (SKI-5C) induces cell death of Wilms' tumor cells in vitro and in vivo.

Authors:  Zhi-Heng Li; Yan-Fang Tao; Li-Xiao Xu; He Zhao; Xiao-Lu Li; Fang Fang; Yi Wu; Jun Lu; Yan-Hong Li; Wei-Wei Du; Jun-Li Ren; Yi-Ping Li; Yun-Yun Xu; Xing Feng; Jian Wang; Wei-Qi He; Jian Pan
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  miR-659-3p is involved in the regulation of the chemotherapy response of colorectal cancer via modulating the expression of SPHK1.

Authors:  Shuyuan Li; Ying Fang; Hai Qin; Wenzheng Fu; Xipeng Zhang
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

4.  Comprehensive gene and microRNA expression profiling reveals a role for miRNAs in the oncogenic roles of SphK1 in papillary thyroid cancer.

Authors:  Weiwei Liang; Zhiwei Xie; Weiling Cui; Yan Guo; Lijuan Xu; Jueheng Wu; Hongyu Guan
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-10       Impact factor: 4.553

5.  Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.

Authors:  Zhao-Xiang Ren; Ya-Fei Zhao; Ting Cao; Xue-Chu Zhen
Journal:  Acta Pharmacol Sin       Date:  2016-07-04       Impact factor: 6.150

Review 6.  Sphingosine-1 Phosphate: A New Modulator of Immune Plasticity in the Tumor Microenvironment.

Authors:  Yamila I Rodriguez; Ludmila E Campos; Melina G Castro; Ahmed Aladhami; Carole A Oskeritzian; Sergio E Alvarez
Journal:  Front Oncol       Date:  2016-10-17       Impact factor: 6.244

Review 7.  Current advances in biomarkers for targeted therapy in triple-negative breast cancer.

Authors:  Brett Fleisher; Charlotte Clarke; Sihem Ait-Oudhia
Journal:  Breast Cancer (Dove Med Press)       Date:  2016-10-06

8.  Metformin inhibits the migration and invasion of esophageal squamous cell carcinoma cells by downregulating the protein kinase B signaling pathway.

Authors:  Yindi He; Xiaojun Tan; Hui Hu; Qinjia Wang; Xi Hu; Xianbin Cai; Yinghong Guan; Binming Chen; Xubin Jing
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

9.  DR5 suppression induces sphingosine-1-phosphate-dependent TRAF2 polyubiquitination, leading to activation of JNK/AP-1 and promotion of cancer cell invasion.

Authors:  You-Take Oh; Ping Yue; Shi-Yong Sun
Journal:  Cell Commun Signal       Date:  2017-05-08       Impact factor: 5.712

Review 10.  Sphingosine 1-Phosphate Signaling as a Target in Hepatic Fibrosis Therapy.

Authors:  Bárbara González-Fernández; Diana I Sánchez; Javier González-Gallego; María J Tuñón
Journal:  Front Pharmacol       Date:  2017-08-25       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.